An Introduction to Headache Disorders
Headache disorders are among the most prevalent and incapacitating conditions worldwide, accounting for nearly three-quarters of all neurological-related disabilities. Primary headache disorders encompass migraine, tension headache, and cluster headache, while medication-overuse headache stands as the prevailing form of secondary headache. Over the past decade, significant advancements in headache management have emerged, revolutionizing the treatment landscape. Notably, novel therapeutic approaches have honed in on targeting the CGRP (calcitonin gene-related peptide) ligand or receptor, thereby reshaping the treatment paradigm for migraines and exhibiting efficacy in combatting cluster headache. Additionally, a fresh avenue of intervention comes in the form of ditans, gepants and monoclonal antibodies, with many forms of medications being delivered by different approaches such as skin patches and nasal sprays, thereby reducing patient burden. These breakthroughs hold great promise in alleviating the burden of headache disorders, fostering improved quality of life for affected individuals.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from our journal touchREVIEWS in Neurology. This is complimented by a range of educational activities developed in collaboration with our leading expert faculty.
Our supporting partners do not constitute an endorsement of the content on this page.
Headache Disorders Content
Stewart Tepper, AAN 2023: Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes the pivotal results of the PROGRESS phase 3 trial, evaluating the efficacy, safety, and tolerability of atogepant for preventive treatment of chronic migraine (CM). This study has very important clinical indications for the use of G pants in prevention of migraine. Atogepant […]
Atogepant for preventive treatment of chronic migraine, PROGRESS phase 3 trial: Richard Lipton, AAN 2023
Atogepant represents a relatively new class of medications called CGRP receptor antagonists, which have shown efficacy in preventing migraines. The PROGRESS phase 3 clinical trial assessed the efficacy of atogepant, an important new oral treatment option for the 8% of people with migraine who live with chronic migraine. Prof. Richard Lipton (Albert Einstein College of Medicine, […]
Stewart Tepper, AAN 2023: Results from the PRODROME trial of ubrogepant for the acute treatment of migraine
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) shares one the most exciting presentations from the 75th AAN Annual Meeting, 2023. The results of the PRODROME study represent a paradigm shift in headache management and the data are a very exciting advance for headache and migraine specialists. Ubrogepant for the Acute Treatment […]
Stewart Tepper, AAN 2023: Significant reduction in migraine days with REN for migraine prevention: A double-blind randomized sham-controlled clinical trial
Migraine affects over 1 billion people worldwide causing significant disability and a socioeconomic burden. Preventive treatment is key to managing migraine, but it is often underutilized. Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes his presentation from the 75th AAN Annual Meeting, 2023. Remote electrical neuromodulation (REN), a non-pharmacological acute migraine treatment, […]
Stewart Tepper, AAN 2023: Phase 3 ASCEND interim analysis – STS101 for the treatment of acute migraine
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes safety and tolerability data from the ASCEND study of STS101 5.2 mg (dihydroergotamine nasal powder) in the acute treatment of migraine attacks with/without aura over 12 months. STS101 is a novel investigational product for rapid and easy nasal delivery. Interim Analysis of […]
Stewart Tepper, AAN 2023: Combination of rizatriptan and AXS-07 – results from the MOMENTUM and INTERCEPT studies
A better understanding of the key areas of unmet need regarding acute migraine therapy may help inform drug development and treatment selection. Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes a poster on data from the MOMENTUM trial, a pivotal trial in the treatment of migraine assessing the efficacy and […]
Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Stewart Tepper, AAN 2022: Phase III MOMENTUM trial results, investigating meloxicam-rizatriptan for the acute treatment of migraine
Meloxicam-Rizatriptan (AXS-07) is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine which combines meloxicam and rizatriptan for the acute treatment of migraine. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) joins us to discuss the phase III MOMENTUM trial aims and design, and the efficacy, safety and tolerability findings of Meloxicam-Rizatriptan for the acute […]
Chia-Chun Chiang, AAN 2021: Real World Efficacy, Tolerability and Safety of Ubrogepant
We had the pleasure of meeting with Chia-Chun Chiang (Mayo Clinic, Rochester, MN, USA) to discuss a real world study of ubrogepant in participants with acute migraine. The abstract entitled: ‘Real World Efficacy, Tolerability and Safety of Ubrogepant’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021. Questions: What is the current […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!